ArticleJournal of cancer research and clinical oncology2026
Targeting SLC6A8 suppresses tumor growth and enhances ferroptosis in hepatocellular carcinoma.
Article in Journal of cancer research and clinical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundHepatocellular carcinoma (HCC) persists as a therapeutic challenge owing to restricted treatment alternatives and the dearth of effective biomarkers. The creatine transporter SLC6A8 has been documented to participate in the progression of various malignancies. However, the role that SLC6A8 plays in HCC remains poorly characterized. Hence, this study aimed to investigate the function of the SLC6A8 in HCC and evaluate its candidacy as a therapeutic target.
methodsBioinformatics analysis, qPCR on tissue specimens, and immunohistochemistry on tissue microarrays were utilized to assess the expression and clinical significance of SLC6A8 in HCC. In vitro assays including cell viability, colony formation, and cell migration, as well as an in vivo subcutaneous xenograft model, were employed to explore the impacts of both genetic silencing of SLC6A8 and pharmacological blockade of SLC6A8 on HCC tumor growth. The anti-tumor effect of SLC6A8 inhibition in combination with the ferroptosis inducer RSL3 in HCC was also examined in cellular and animal models.
resultsOur findings revealed that SLC6A8 is notably upregulated in HCC tissues and is associated with a poor prognosis. SLC6A8 knockdown suppressed cell proliferation and migration of HCC cells. RGX-202 also demonstrated potent antitumor efficacy in HCC cells both in vitro and in vivo. Moreover, SLC6A8 inhibition augmented cellular susceptibility to ferroptosis and significantly enhanced the anti-tumor efficacy of the ferroptosis inducer RSL3 in xenograft models of HCC.
conclusionThese findings underscore SLC6A8 as a promising therapeutic target, and its inhibitor combined with ferroptosis inducers may serve as an innovative treatment strategy for improving the therapeutic effect in HCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.